Home > Gastroenterology > Spore therapy cuts C. difficile reinfection by 68% in 8-week study

Spore therapy cuts C. difficile reinfection by 68% in 8-week study


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The New England Journal of Medicine
Reuters Health -  19/01/2022 - An experimental three-day therapy that adds Firmicutes spores to the gut can reduce the risk of Clostridioides difficile reinfection by 68% according to the results from an eight-week phase 3 study reported in the New England Journal of Medicine.  Of the 89 volunteers who received the treatment, known as SER-109, 12% had a C. difficile recurrence versus 40% of the 93 patients who received 12 placebo capsules over 3 days (P<0.001).  Side effects, most of which were gastrointestinal, were seen in 88% of spore recipients and 87% of placebo patients. Most of the adverse events were ranked as mild or moderate.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on